Abstract:Animal models are crucial to understanding human disease biology and developing new therapies. By far the most common animal used to investigate prevailing questions about human disease is the mouse. Mouse models are powerful tools for research as their small size, limited lifespan, and defined genetic background allow researchers to easily manipulate their genome and maintain large numbers of animals in general laboratory spaces. However, it is precisely these attributes that make them so different from humans and explains, in part, why these models do not accurately predict drug responses in human patients. This is particularly true of the neurofibromatoses (NFs), a group of genetic diseases that predispose individuals to tumors of the nervous system, the most common of which is Neurofibromatosis type 1 (NF1). Despite years of research, there are still many unanswered questions and few effective treatments for NF1. Genetically engineered mice have drastically improved our understanding of many aspects of NF1, but they do not exemplify the overall complexity of the disease and some findings do not translate well to humans due to differences in body size and physiology. Moreover, NF1 mouse models are heavily reliant on the Cre-Lox system, which does not accurately reflect the molecular mechanism of spontaneous loss of heterozygosity that accompanies human tumor development. Spontaneous and genetically engineered large animal models may provide a valuable supplement to rodent studies for NF1. Naturally occurring comparative models of disease are an attractive prospect because they occur on heterogeneous genetic backgrounds and are due to spontaneous rather than engineered mutations. The use of animals with naturally occurring disease has been effective for studying osteosarcoma, lymphoma, and diabetes. Spontaneous NF-like symptoms including neurofibromas and malignant peripheral nerve sheath tumors (MPNST) have been documented in several large animal species and share biological and clinical similarities with human NF1. These animals could provide additional insight into the complex biology of NF1 and potentially provide a platform for pre-clinical trials. Additionally, genetically engineered porcine models of NF1 have recently been developed and display a variety of clinical features similar to those seen in NF1 patients. Their large size and relatively long lifespan allow for longitudinal imaging studies and evaluation of innovative surgical techniques using human equipment. Greater genetic, anatomic, and physiologic similarities to humans enable the engineering of precise disease alleles found in human patients and make them ideal for preclinical pharmacokinetic and pharmacodynamic studies of small molecule, cellular, and gene therapies prior to clinical trials in patients. Comparative genomic studies between humans and animals with naturally occurring disease, as well as preclinical studies in large animal disease models, may help identify new targets for therapeutic intervention and expedite the translation of new therapies. In this review, we discuss new genetically engineered large animal models of NF1 and cases of spontaneous NF-like manifestations in large animals, with a special emphasis on how these comparative models could act as a crucial translational intermediary between specialized murine models and NF1 patients.

Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment

Molecular and Cellular Mechanisms of Learning Disabilities: a Focus on NF1.

Drosophila Contributions towards Understanding Neurofibromatosis 1

Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1

Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas

Transient Inhibition of the Erk Pathway Prevents Cerebellar Developmental Defects and Improves Long-Term Motor Functions in Murine Models of Neurofibromatosis Type 1

RAS and beyond: the many faces of the neurofibromatosis type 1 protein

NF1+/ex42del miniswine model the cellular disruptions and behavioral presentations of NF1‐associated cognitive and motor impairment

NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development.

Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1

Unraveling neuronal and metabolic alterations in neurofibromatosis type 1

Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care

Neurofibromin Loss of Function Drives Excessive Grooming in Drosophila

Human stem cell modeling in neurofibromatosis type 1 (NF1)

Advances in Diagnosis and Treatment of Neurofibromatosis Type 1

Effect of Neurofibromatosis Type I Mutations on a Novel Pathway for Adenylyl Cyclase Activation Requiring Neurofibromin and Ras.

Neurofibromin deficiency alters the patterning and prioritization of motor behaviors in a state-dependent manner

NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy

Translating current basic research into future therapies for neurofibromatosis type 1

Tumorigenesis in neurofibromatosis type 1: role of the microenvironment

The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1